Fibrobiologics Inc (FBLG) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access FBLG Annual Balance Sheets →
The data below summarizes Fibrobiologics Inc's balance sheet position from Jun 30 2025 to Jun 30 2026, enabling a period-by-period comparison of financial strength.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent3.52
Cash & Short-term Investments3.00
Other Current Assets1.81
Prepaid Expense, Current AS0.53
Total Current Assets5.85
Equipment/Property/Plant Net1.29
Other Assets, Noncurrent0.79
Operating Lease Right Of Use Asset2.21
Total Assets7.93
Liabilities
Accounts Payable and Accrued Liabilities, Current LI1.82
Loans Payable, Current NO0.12
Other Liabilities, Current0.27
Total Current Liabilities2.21
Total Long-term Debt0.00
Other liabilities, Noncurrent1.08
OperatingLeaseLiabilityNoncurrent1.51
Sepa Put Option Liability0.01
Operating Lease Liability Current0.72
Total Liabilities3.29
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock67.92
Retained Earnings / Accumulated Deficit-63.28
Other Equity0.00
Common Stockholder's Equity4.64
Total Stockholder's Equity4.64
Liabilities & Stockholder's Equity7.93
4 historic quarters locked

Sign in to unlock the full Fibrobiologics Inc balance sheet history.

About Fibrobiologics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-328454

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.